Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Note: Metadata listed "Chronoscale Holdings Corp" is inconsistent with the filing text which identifies Ekso Bionics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date: August 9, 2016
Event: Entry into a Material Definitive Agreement for a public offering of common stock.

Key Financial Metrics and Transaction Details

  • Offering Size: 3,750,000 shares of Common Stock.
  • Offering Price: $4.00 per share.
  • Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 562,500 additional shares.
  • Expected Net Proceeds: Approximately $13.7 million (after underwriting discounts, commissions, and estimated offering expenses).
  • Expected Closing Date: August 12, 2016.
  • Lock-Up Period: Company, directors, and executive officers agreed not to sell or transfer Common Stock for 90 days following August 9, 2016, without consent.

Material Changes and Adjustments

This filing triggers significant adjustments to previously issued securities due to full-ratchet anti-dilution provisions:

  • Series A Convertible Preferred Stock: Conversion price adjusted downward from $7.07 to $3.74 per share.
  • 2015 Warrants: Exercise price adjusted downward from $8.75 to $3.74 per share.
  • Impact on Conversion: The 3,443 outstanding Preferred Shares will now convert into 920,588 shares of Common Stock (increased from the prior conversion count).
  • Outstanding Warrants: 2,121,642 shares of Common Stock remain subject to the 2015 Warrants.

Guidance, Outlook, and Risks

Management Commentary: The Company is utilizing an effective shelf registration statement (Form S-3, No. 333-205168) to facilitate this offering. The primary purpose is to raise capital for general corporate purposes, though specific allocation of funds is not detailed in this excerpt.

Risks and Contingencies:

  • Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
  • Dilution: The downward adjustment of conversion and exercise prices for existing preferred stock and warrants significantly increases the potential dilution to common shareholders.
  • Legal Opinions: The validity of the issuance relies on the opinion of Nutter, McClennen & Fish, LLP.

Investor Verification Checklist

  • Verify the final closing date and actual net proceeds received (expected $13.7 million).
  • Confirm the exact number of shares issued upon exercise of the over-allotment option (if any).
  • Review the updated capitalization table to reflect the increased conversion count of Series A Preferred Stock (920,588 shares).
  • Check subsequent filings for the specific use of proceeds and any changes to the 90-day lock-up agreement.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.